S213
Clinical - Breast
ESTRO 2026
occurred. Grade 1 epidermitis was seen in 10.5%, asthenia in 15%, pain in 10.5%, and edema in 5.2%. Late toxicity occurred in 21%: Grade 1 edema in 5.2%, Grade 1 fibrosis in 10.5%, and Grade 2 fibrosis in 5.2%. Pain resolved in 6 months in 10.5% of patients.Aesthetic results were very good in 47.3%, good in 47.3%, and fair in 5.2%. Conclusion: SPBI reirradiation is a safe and effective treatment for selected patients, with minimal early and late toxicity and favorable aesthetic outcomes. These findings suggest lower toxicity compared to lower-technology Abeloos, C. H., Purswani, J. M., Galavis, et al. (2023). Different Re-Irradiation Techniques after Breast- Conserving Surgery for Recurrent or New Primary Breast Cancer. Current oncology (Toronto, Ont.), 30(1), 1151–1163. https://doi.org/10.3390/curroncol30010088Amraee, A., Mokhayeri, Y., Gholami, M., et al. (2025). Evaluation of normal tissue complications in breast cancer re- irradiation: a meta-analysis study. Clinical & techniques. References: translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(3), 805–815. https://doi.org/10.1007/s12094-024-03632-z Keywords: Reirradiation, breast cancer, SPBI Digital Poster Highlight 674 Predictors for LRR in early breast cancer patients with isolated tumor cells and micro/macro metastases treated with BCS, SLNB followed by adjuvant RT Kurian Joseph 1,2 , Ayoola Ademola 3 , David Sinn 2 , Hali Morrison 4 , Hong-wei Liu 5 , Aswin Abraham 1 , Zsolt Gabos 1 , Keith Tankel 1 , Susan Chafe 1 , Karen King 6 1 Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Canada. 2 Department of Oncology, University of Alberta, Edmonton, Canada. 3 Cancer Advanced Analytics Cancer Research & Analytics, Cancer care Alberta, Calgary, Canada. 4 Department of Oncology , Physics and Astronomy, University of Calgary, Calgary, Canada. 5 Department of Radiation Oncology, Central Alberta cancer Centre, Red Deer, Canada. 6 Department ofMedical Oncology, Cross Cancer Institute, Edmonton, Canada Purpose/Objective: Axillary lymph node status is one of the key prognostic factors in the management of breast cancer (BC) that could subsequently determine the benefit of adjuvant treatments. Adjuvant regional nodal radiotherapy (ARRT) is routinely used for patients with lymph nodal involvement. However, the prognostic significance of
Previous Randomized Trials. J Clin Oncol Keywords: partial breast irradiation, secondary malignancies
Digital Poster 631 Stereotactic Body Radiotherapy in Local Recurrence of Breast Cancer
Patricia Murina, Millia Galetto, Daniela Angel Schutte, Deborah Middendorf, Monica Martinez, Valentina Gregorat, Franco Barolo, Daniel Venencia, Silvia Zunino Radiation Oncology, Instituto Zunino, Cordoba, Argentina Purpose/Objective: Breast cancer is the most common malignancy in women worldwide. Despite therapeutic advances, some patients develop local recurrence after conservative surgery or mastectomy. Re-irradiation of the surgical bed following conservative surgery has emerged as a feasible option to limit cumulative toxicity and maintain local control. Stereotactic Body Radiotherapy (SBRT) allows precise, conformal dose delivery. Partial Breast Irradiation with SBRT (SPBI) offers ablative doses in few fractions while sparing healthy tissue. This study evaluates early and late toxicity of SPBI in 5 fractions for local breast cancer recurrence and assesses cosmetic outcomes. Material/Methods: A retrospective review was performed on patients treated with SPBI between June 2022 and June 2025. All patients had previously undergone breast irradiation via 2D, 3D, IMRT, or sIMRT techniques. Early (less than 3 months) and late (more than 3 months) toxicity were assessed using CTCAE V.5.0 criteria. Aesthetic results were categorized as poor, fair, good, or very good. All patients had local recurrence, with tumor resection and titanium clips placed at the surgical bed. CT-based virtual simulation and vacuum immobilization were used. Left-sided breast cancer patients received respiratory gating. Treatment was delivered using SBRT + IGRT with volumetric arc therapy (VMAT), administering 30 Gy to the PTV_Eval in 5 fractions, yielding an EQD2 of 54 Gy. Results: Nineteen patients were included, with a mean age of 64 years (range: 46–76). Six tumors were right-sided, and 13 left-sided. The average time from initial irradiation to re-irradiation was 14 years (range: 1–37). The average follow-up was 15.7 months (range: 3.1– 37.1). Local control was achieved in 100% of patients at the last follow-up. The mean PTV_Eval volume relative to the total breast volume was 22.66% (range: 14–33%). The mean heart dose was 0.28 Gy (right) and 0.31 Gy (left), with gating.Regarding early toxicity, 68% had no toxicity, and no Grade 2-3 early toxicity
Made with FlippingBook - Share PDF online